e-IMPAQc Systematic Assessment of Patient Reported Outcomes in Cancer Care
NCT06168435 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 500
Last updated 2023-12-13
Summary
Purpose: The Electronic Implementation of Patient and Caregiver Reported Outcomes across cancer centres in Quebec project, or e-IMPAQc, was launched in 2017. e-IMPAQc's goal is to actively engage patients, their caregivers, healthcare professionals (HCPs), managers, policy makers, researchers and IT personnel to co-develop, implement, and evaluate an evidence-informed electronic patient-reported outcomes (e-PRO) screening and management program across Quebec.
Methods: e-IMPAQc built on the Improving Patient Experience and Health Outcomes Collaborative (iPEHOC) project, the first initiative in the province to implement e-PRO screening and was rolled out in three phases. e-IMPAQc has five main components: 1) primary and secondary standardized e-PRO questionnaires and algorithm; 2) summary report for clinicians with alert system; 3) summary report for patients, with tailored notifications regarding symptom severity; 4) self-management fact sheets library; and 5) clinical dashboard. Phase 1 included initiating change management and the co-development of the e-PRO algorithm with patients, their caregivers, HCPs, managers, policy makers, researchers and IT personnel (herein collectively referred as stakeholders) across seven cancer centres. The iPEHOC algorithm was used as a starting point given its successful implementation in one of the participating cancer centres for several years. Phase 1 also included feasibility work to establish a caregiver-reported outcomes (CROs) algorithm as well as the identification and configuration of appropriate electronic platforms on which to house e-IMPAQc. In Phase 2 the focus was on preparing for imminent implementation through workflow mapping and putting in place implementation support (e.g., site coordinators). A pilot of e-IMPAQc (excluding CROs) was also undertaken at one of the participating centres. In Phase 3, e-IMPAQc is being sequentially rolled out to as many cancer centres as possible and then evaluated. Qualitative and quantitative methods are used to document the process of implementation, patient and caregiver, and knowledge transfer (KT) outcomes.
Conditions
Interventions
- OTHER
-
eIMPAQc
e-IMPAQc has five main components: 1) primary and secondary standardized e-PRO questionnaires and algorithm; 2) summary report for clinicians with alert system; 3) summary report for patients, with tailored notifications regarding symptom severity; 4) self-management fact sheets library; and 5) clinical dashboard.
Sponsors & Collaborators
-
St. Mary's Research Center, Canada
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-11-03
- Primary Completion
- 2024-12-31
- Completion
- 2024-12-31
Countries
- Canada
Study Locations
More Related Trials
-
Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)
NCT06943495 ·Status: RECRUITING ·Phase: PHASE1
-
Electronic Patient Self-Reported Outcomes to Improve Cancer Management and Patient Experiences
NCT02847715 ·Status: COMPLETED ·Phase: NA
-
Electrical Patient Reported Outcome of Prostate Cancer RadioTherapy
NCT05187026 ·Status: UNKNOWN
-
Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy
NCT03619655 ·Status: TERMINATED ·Phase: PHASE1
-
Feasibility Study of an ePRO Monitoring for Patients With Multiple Myeloma and Development of Item Lists
NCT05036863 ·Status: COMPLETED
-
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
NCT03561220 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer
NCT01982786 ·Status: COMPLETED ·Phase: NA
-
CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study
NCT04384770 ·Status: ACTIVE_NOT_RECRUITING
-
Hypo-fractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer
NCT01059513 ·Status: COMPLETED
-
Single Fractions SBRT for Prostate Cancer
NCT04004312 ·Status: RECRUITING ·Phase: NA
-
Toward a Comprehensive Supportive Care Intervention for Older or Frail Men With mCRPC
NCT04193657 ·Status: COMPLETED
-
Testing and Evaluating the Collection of Patient Reported Outcomes In Cancer Care Using Innovative Approaches
NCT05911672 ·Status: UNKNOWN ·Phase: NA
-
Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer
NCT06927635 ·Status: RECRUITING ·Phase: PHASE2
-
3TMPO (Triple-Tracer Strategy Against Metastatic Prostate Cancer
NCT04000776 ·Status: COMPLETED
-
Hypofractionated Stereotactic Boost in Prostate Cancer
NCT01596816 ·Status: COMPLETED ·Phase: PHASE2
-
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
NCT02624518 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy
NCT03160794 ·Status: RECRUITING ·Phase: NA
-
Prospective Prostate Cancer and Patient-reported Outcomes Registry
NCT04694924 ·Status: RECRUITING
-
Intestinal Microbiota in Prostate Cancer Patients as a Biomarker for Radiation-INduced Toxicity (IMPRINT)
NCT04638049 ·Status: COMPLETED ·Phase: NA
-
Post-Prostatectomy Linac-Based Ultrahypofractionated Radiotherapy for Patients With Localized Prostate Cancer
NCT04067570 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Stereotactic Prostate Radiotherapy With Dose Escalation Focused on the "Dominant Intra-prostatic Lesion" (DIPL) Delineated by Multi-parametric MRI and 68Ga-PSMA PET (Prostate-SIB-PSMA)
NCT05599737 ·Status: UNKNOWN ·Phase: NA
-
Prostate Cancer Patient Management With 18F-DCFPyL PET/CT
NCT03459820 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2/PHASE3
-
Evaluation of the Dose Received by the Prostate With in Vivo Dosimetry in Patients Treated With Daily IGRT Associated With IMRT Using Two Repositioning Techniques for Localized Prostate Cancer
NCT02279693 ·Status: TERMINATED ·Phase: NA
-
PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer
NCT03594760 ·Status: RECRUITING ·Phase: PHASE3
-
Intensity Modulated Versus Interstitial - Radiation Therapy
NCT00407875 ·Status: UNKNOWN ·Phase: NA